No Data
Pharmaceutical stocks generally rose, with KCP Pharmaceutical (02171) increasing by 25.29%. Institutions expect that after the first quarter report, the pharmaceutical Sector is likely to see an overall performance reversal in the Industry.
Jinwu Financial News | Pharmaceutical stocks have generally risen, with Keji Pharmaceutical (02171) up 25.29%, INNOCARE (09969) up 14.58%, REMEGEN (09995) up 12.88%, Yiming Anke (01541) up 12.25%, Lepu Biopharma (02157) up 10.67%, YSB (09885) up 6.88%, and Gushengtang (02273) up 6.71%. The Hong Kong stock Pharmaceutical ETF has risen 3.59%, and the Hong Kong Stock Connect Yinhua CSI Innovative Drugs Industry ETF has risen 4.05%. Ping An Securities stated that on January 17, 2025, the National Healthcare Security Administration will hold a '
ImmuneOnco Biopharmaceuticals Completes Disposal of Subsidiary; Shares Plunge 15%
Hong Kong stock early report | The humanoid robot sector welcomes another Bullish market. Sands China last year's net profit increased by over 50% year on year.
① State Council meeting: Research and introduce a series of new open measures in the Medical, financial and other fields. ② He Lifeng had a video call with US Treasury Secretary Yellen, exchanging in-depth opinions on important issues in the economic field between China and the US. ③ Shenzhen: A special policy for humanoid Robots will be announced soon, allocating special funds for AI and Robots in the city's major Technology projects. ④ DeepSeek is "low-key" participating in the 2025 Global Developer Pioneer Conference.
IMMUNEONCO-B (01541) has completed the sale of all equity in Shanghai Zhang Tou Yao New Technology Development.
IMMUNEONCO-B (01541) announced that all the preconditions under the agreement have been met, and the delivery has been completed according to the agreement...
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Hong Kong stocks fluctuate | IMMUNEONCO-B (01541) surged over 15% in the afternoon, with data from the clinical trial of combined chemotherapy IMM2510 expected to be released in the second half of the year.
IMMUNEONCO-B (01541) rose over 15% in the afternoon, as of the time of writing, it is up 14.4% at 5.56 HKD, with a trading volume of 91.407 million HKD.